Research Interests:Studies are focused toward developing vaccines and therapeutics to combat militarily relevant agents of disease. Current research is focused on developing and testing DNA vaccines or immunotherapeutics for hantaviruses, filoviruses (Ebola and Marburg viruses), anthrax, Venezuelan equine encephalitis virus, vaccinia virus, Crimean Congo hemorrhagic fever virus, Lassa virus, and Rift Valley fever virus. Unique research facilities are available for containment of special pathogens. Vaccine studies span basic research to clinical trials.
Hooper, J.W., D. Custer, E. Thompson, and C.S. Schmaljohn (2001). DNA Vaccination with the Hantaan Virus M Gene Protects Hamsters Against Three of Four HFRS Hantaviruses and Elicits a High-Titer Neutralizing Antibody Response in Rhesus Monkeys. J. Virol. 75, 8469-8477.
Hooper J.W., Larsen, T., Custer, D. and Schmaljohn, C.S. (2001). A lethal disease model for hantavirus pulmonary syndrome. Virology, 289, 6-14.
Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. (2000). DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology. 266,329-39.
McClain DJ, Summers PL, Harrison SA, Schmaljohn AL, Schmaljohn CS. (2000). Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J Med Virol. 60,77-85.
Guttieri, M., Bookwalter, C., and Schmaljohn, C. (2000). Expression of a human neutralizing monoclonal antibody to Puumala virus in stably-transformed insect cells. J. Immunol Methods. 246,97-108.
Meyer B. J., and Schmaljohn, C. (2000). Accumulation of terminally deleted RNAs may play a role in Seoul virus persistence. J Virol., 74,1321-31.
Faculty members: Update your contact information and create a profile.